Skip to Main Content
Tufts University Marketplace
Toggle Main Navigation
Enter a site search term and use the ENTER KEY to submit your search
My Account
Register
Log In
Items in Cart 0
0
All Stores
Product Categories
Athletics
Classes/Courses
Conferences
Continuing Education
Fees
Merchandise
Services
Tickets/Events
Tufts CSDD Impact Reports - Single Issue Electronic (2012-2016)
Mall
Tufts Center for the Study of Drug Development
Tufts CSDD Reports
Tufts CSDD Impact Reports - Single Issue Electronic (2012-2016)
Tufts CSDD Single Issue Electronic Impact Reports ($150)
Tufts CSDD Impact Report Archive (1999-2011)
Price:
$150.00
Select One
Select One
18(6) - Nov/Dec 16: Pediatric Regulatory Science, Clinical Trial Networks Hold Promise for Studies
18(5) - Sep/Oct 16: Diabetes Drug Development is Riskier Compared to All Drug Development
18(4) - Jul/Aug 16: Global Regenerative Medicine Market is Poised for Strong Growth
18(3) - May/Jun 16: Expected Growth in PBM Exclusion Lists Poses a Challenge to Drug Developers
18(2) - Mar/Apr 16: Promise of Immuno-Oncology Therapies is Boosting R&D Funding, Alliances
18(1) - Jan/Feb 16: Amendments Reduce Number of Patients, But at High Cost, Longer Study Time
17(6) - Nov/Dec 15: First-in-Class Drugs in Competitive Development Races with Later Entrants
17(5) - Sep/Oct 15: Adverse Drug Event Reporting in US Beset by Incompleteness & Inaccuracy
17(4) - Jul/Aug 15: Vaccine Products in the R&D Pipeline Have More than Tripled Since 2005
17(3) - May/Jun 15: Personalized Medicine Gains Traction But Still Faces Multiple Challenges
17(2) - Mar/Apr 15: Biosimilars Entering the US Market Are Likely to Face Multiple Challenges
17(1) - Jan/Feb 15: High Turnover, Protocol Noncompliance Plague the Global Site Landscape
16(6) - Nov/Dec 14: CNS Drugs Take Longer to Develop, Have Lower Success Rates, Than Other Drugs
16(5) - Sep/Oct 14: Protocol Design Optimization Starting to Improve Study Performance
16(4) - Jul/Aug 14: Patients Face New Challenges Accessing a Growing Number of Orphan Drugs
16(3) - May/Jun 14: Collaboration & Risk-Sharing Programs Experience Longer Development Times
16(2) - Mar/Apr 14: Drug Sponsors Tread Cautiously Using Social Media to Aid Clinical Research
16(1) - Jan/Feb 14: New Breakthrough Therapy Designation Program Aims to Cut Clinical Trial Time
15(6) - Nov/Dec 13: Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically
15(5) - Sep/Oct 13: Causes of Clinical Failures Vary Widely By Therapeutic Class, Phase of Study
15(4) - Jul/Aug 13: Annual Approvals For Neglected Diseases Rose from 2.6 in 2000-08 to 5 in 2009-12
15(2) - Mar/Apr 13: Global Site Landscape Remains Highly Fragmented With Variable Performance
15(3) - May/Jun 13: Clinical Success Rates For New Cancer Drugs Double While More Enter Testing
15(1) - Jan/Feb 13: 89% of Trials Meet Enrollment, But Timelines Slip, Half of Sites Under-Enroll
14(6) - Nov/Dec 12: One in Five Procedures Generates Extraneous Clinical Trials Data
14(5) - Sep/Oct 12: Oncology Drugs Get Faster Approvals Than Non-Oncology Drugs in US
14(4) - Jul/Aug 12: US Offers Patients Faster, Greater Access to Cancer Drugs Than Europe
14(3) - May/Jun 12: User Fee Era in US Currently Poses Mixed Regulatory Burden For Sponsors
14(2) - Mar/Apr 12: Pace of CNS Drug Development and FDA Approvals Lags Other Drug Classes
14(1) - Jan/Feb 12: Study Monitor Workload High & Varied with Wide Disparity by Global Region
Quantity:
Add To Cart